SG11201509450QA - Methods to produce particles comprising therapeutic proteins - Google Patents

Methods to produce particles comprising therapeutic proteins

Info

Publication number
SG11201509450QA
SG11201509450QA SG11201509450QA SG11201509450QA SG11201509450QA SG 11201509450Q A SG11201509450Q A SG 11201509450QA SG 11201509450Q A SG11201509450Q A SG 11201509450QA SG 11201509450Q A SG11201509450Q A SG 11201509450QA SG 11201509450Q A SG11201509450Q A SG 11201509450QA
Authority
SG
Singapore
Prior art keywords
methods
therapeutic proteins
produce particles
particles
produce
Prior art date
Application number
SG11201509450QA
Inventor
Sarah Marquette
Andrew Yates
Claude Peerboom
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201509450Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP13168674.3A external-priority patent/EP2805708A1/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SG11201509450QA publication Critical patent/SG11201509450QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201509450QA 2013-05-22 2014-05-21 Methods to produce particles comprising therapeutic proteins SG11201509450QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13168674.3A EP2805708A1 (en) 2013-05-22 2013-05-22 Methods to produce particles comprising therapeutic proteins
EP14161988 2014-03-27
PCT/EP2014/060450 WO2014187863A1 (en) 2013-05-22 2014-05-21 Methods to produce particles comprising therapeutic proteins

Publications (1)

Publication Number Publication Date
SG11201509450QA true SG11201509450QA (en) 2015-12-30

Family

ID=50877246

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509450QA SG11201509450QA (en) 2013-05-22 2014-05-21 Methods to produce particles comprising therapeutic proteins

Country Status (14)

Country Link
US (1) US20160090415A1 (en)
EP (1) EP2999459A1 (en)
JP (1) JP2016519152A (en)
KR (1) KR20160009690A (en)
CN (1) CN105338961A (en)
AU (1) AU2014270439A1 (en)
BR (1) BR112015028986A2 (en)
CA (1) CA2912730A1 (en)
CL (1) CL2015003420A1 (en)
EA (1) EA201592222A1 (en)
HK (1) HK1214964A1 (en)
MX (1) MX2015015899A (en)
SG (1) SG11201509450QA (en)
WO (1) WO2014187863A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528248A (en) 2016-07-18 2019-10-10 ティシュージェン, インク. Methods and compositions for maintaining biomolecule conformation and structural integrity
CN112336873B (en) * 2020-08-04 2022-04-19 华南理工大学 Protein type nanoparticle for multi-specific antibody delivery and application and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100201352B1 (en) * 1995-03-16 1999-06-15 성재갑 Single shot vaccine formulation
EP2044934A1 (en) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof

Also Published As

Publication number Publication date
HK1214964A1 (en) 2016-08-12
BR112015028986A2 (en) 2017-07-25
AU2014270439A1 (en) 2015-12-17
CN105338961A (en) 2016-02-17
JP2016519152A (en) 2016-06-30
EA201592222A1 (en) 2016-08-31
CA2912730A1 (en) 2014-11-27
CL2015003420A1 (en) 2016-09-30
WO2014187863A1 (en) 2014-11-27
KR20160009690A (en) 2016-01-26
MX2015015899A (en) 2016-07-15
EP2999459A1 (en) 2016-03-30
US20160090415A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
IL276819A (en) Nucleic acids encoding human antibodies to sialyl-lewisa
IL287516A (en) Therapeutic uses of empagliflozin
HRP20190101T1 (en) Therapeutic uses of empagliflozin
HK1219964A1 (en) Continuous purification of therapeutic proteins
HK1213818A1 (en) Therapeutic uses of empagliflozin
IL286759A (en) Therapeutic methods and compositions
PL3063275T3 (en) Therapeutic nuclease-albumin fusions and methods
SG11201505198WA (en) Protein purification methods
LT2981271T (en) Therapeutic uses of empagliflozin
SG11201603028SA (en) Purification of proteins
IL245524A0 (en) New methods to produce active tert
IL244453A0 (en) Methods of determining response to therapy
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
HK1220991A1 (en) Formulations and methods for increased recombinant protein production
HK1214964A1 (en) Methods to produce particles comprising therapeutic proteins
EP2996684A4 (en) Therapeutic methods
GB201320209D0 (en) Improvements in or relating to protein Micro-nets
GB201319255D0 (en) Therapeutic compositions and methods